Insider Trading Alert - CME, COL, BCR, LNKD And OVTI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 17, 2013, 129 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $69.90 to $563,062,500.00.

Highlighted Stocks Traded by Insiders:

CME Group (CME) - FREE Research Report

Clegg Jackie M who is Director at CME Group sold 2,000 shares at $81.10 on Dec. 17, 2013. Following this transaction, the Director owned 7,155 shares meaning that the stake was reduced by 21.85% with the 2,000-share transaction.

The shares most recently traded at $83.16, up $2.06, or 2.48% since the insider transaction. Historical insider transactions for CME Group go as follows:

  • 4-Week # shares sold: 2,516
  • 12-Week # shares bought: 350
  • 12-Week # shares sold: 5,748
  • 24-Week # shares bought: 350
  • 24-Week # shares sold: 12,085

The average volume for CME Group has been 1.5 million shares per day over the past 30 days. CME Group has a market cap of $27.6 billion and is part of the financial sector and financial services industry. Shares are up 63.59% year-to-date as of the close of trading on Tuesday.

CME Group Inc. operates the CME, CBOT, NYMEX COMEX, and KCBT futures exchanges worldwide. It operates CBOT exchange, a marketplace for trading agricultural and the U.S. The stock currently has a dividend yield of 2.19%. The company has a P/E ratio of 28.9. Currently there are 7 analysts that rate CME Group a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CME - FREE

TheStreet Quant Ratings rates CME Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CME Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Rockwell Collins (COL) - FREE Research Report

Abzug Barry M who is Sr. VP, Corporate Development at Rockwell Collins sold 1,456 shares at $71.67 on Dec. 17, 2013. Following this transaction, the Sr. VP, Corporate Development owned 13,671 shares meaning that the stake was reduced by 9.63% with the 1,456-share transaction.

The shares most recently traded at $71.18, down $0.49, or 0.69% since the insider transaction. Historical insider transactions for Rockwell Collins go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares sold: 57,350

The average volume for Rockwell Collins has been 806,600 shares per day over the past 30 days. Rockwell Collins has a market cap of $9.7 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 23.53% year-to-date as of the close of trading on Tuesday.

Rockwell Collins, Inc. designs, produces, and supports communications and aviation electronics for commercial and military customers worldwide. It operates in two segments, Government Systems and Commercial Systems. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 15.7. Currently there are 5 analysts that rate Rockwell Collins a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COL - FREE

TheStreet Quant Ratings rates Rockwell Collins as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Rockwell Collins Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

C.R. Bard (BCR) - FREE Research Report

Collins Timothy P who is Group President at C.R. Bard sold 3,347 shares at $133.23 on Dec. 17, 2013. Following this transaction, the Group President owned 48,439 shares meaning that the stake was reduced by 6.46% with the 3,347-share transaction.

The shares most recently traded at $132.19, down $1.04, or 0.78% since the insider transaction. Historical insider transactions for C.R. Bard go as follows:

  • 4-Week # shares sold: 26,012
  • 12-Week # shares sold: 37,309
  • 24-Week # shares sold: 55,776

The average volume for C.R. Bard has been 584,600 shares per day over the past 30 days. C.R. Bard has a market cap of $10.4 billion and is part of the health care sector and health services industry.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. Currently there are 6 analysts that rate C.R. Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCR - FREE

TheStreet Quant Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full C.R. Bard Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LinkedIn (LNKD) - FREE Research Report

Sze David L who is Director at LinkedIn sold 6,250 shares at $227.99 on Dec. 17, 2013. Following this transaction, the Director owned 166,938 shares meaning that the stake was reduced by 3.61% with the 6,250-share transaction.

The shares most recently traded at $210.34, down $17.65, or 8.39% since the insider transaction. Historical insider transactions for LinkedIn go as follows:

  • 4-Week # shares sold: 6,250
  • 12-Week # shares sold: 48,087
  • 24-Week # shares sold: 127,372

The average volume for LinkedIn has been 2.2 million shares per day over the past 30 days. LinkedIn has a market cap of $23.2 billion and is part of the technology sector and internet industry. Shares are up 98.65% year-to-date as of the close of trading on Tuesday.

LinkedIn Corporation operates an online professional network. The company has a P/E ratio of 760.3. Currently there are 14 analysts that rate LinkedIn a buy, no analysts rate it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNKD - FREE

TheStreet Quant Ratings rates LinkedIn as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and disappointing return on equity. Get the full LinkedIn Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

OmniVision Technologies (OVTI) - FREE Research Report

Hsu Wenliang William who is Director at OmniVision Technologies sold 2,000 shares at $16.76 on Dec. 17, 2013. Following this transaction, the Director owned 10,500 shares meaning that the stake was reduced by 16% with the 2,000-share transaction.

The shares most recently traded at $16.83, up $0.07, or 0.42% since the insider transaction. Historical insider transactions for OmniVision Technologies go as follows:

  • 24-Week # shares sold: 6,646

The average volume for OmniVision Technologies has been 1.4 million shares per day over the past 30 days. OmniVision Technologies has a market cap of $928.9 million and is part of the technology sector and electronics industry. Shares are up 17.9% year-to-date as of the close of trading on Tuesday.

OmniVision Technologies, Inc. engages in designing, developing, and marketing semiconductor image-sensor devices worldwide. The company has a P/E ratio of 11.4. Currently there are 4 analysts that rate OmniVision Technologies a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OVTI - FREE

TheStreet Quant Ratings rates OmniVision Technologies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full OmniVision Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)